Logo

Artemis Will Make Knock-outs For Merck

Jun 10, 2002

NEW YORK, June 10-Exelixis subsidiary Artemis Pharmaceuticals has struck a deal with Merck to create customized mouse models of disease, the company said today.

 

Merck will provide genetic specifications for the mice, and Artemis will use its gene inactivation technology to develop the strains.

 

The companies did not disclose financial details of the agreement.

 

Exelixis acquired Cologne, Germany-based Artemis in 2001.

 

For more details, see the company website.

Breaking News
The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.